- Home
- RIGL vs SPOK Comparison
RIGL vs SPOK Comparison
Compare RIGL & SPOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- SPOK
- Stock Information
- Founded
- RIGL 1996
- SPOK 2004
- Country
- RIGL United States
- SPOK United States
- Employees
- RIGL N/A
- SPOK N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- SPOK Telecommunications Equipment
- Sector
- RIGL Health Care
- SPOK Telecommunications
- Exchange
- RIGL Nasdaq
- SPOK Nasdaq
- Market Cap
- RIGL 335.5M
- SPOK 318.9M
- IPO Year
- RIGL 2000
- SPOK 1992
- Fundamental
- Price
- RIGL $18.98
- SPOK $17.38
- Analyst Decision
- RIGL Buy
- SPOK Hold
- Analyst Count
- RIGL 5
- SPOK 1
- Target Price
- RIGL $36.40
- SPOK $15.00
- AVG Volume (30 Days)
- RIGL 206.5K
- SPOK 118.0K
- Earning Date
- RIGL 08-05-2025
- SPOK 07-23-2025
- Dividend Yield
- RIGL N/A
- SPOK 7.17%
- EPS Growth
- RIGL N/A
- SPOK N/A
- EPS
- RIGL 2.08
- SPOK 0.77
- Revenue
- RIGL $203,077,000.00
- SPOK $139,038,000.00
- Revenue This Year
- RIGL $14.41
- SPOK $2.26
- Revenue Next Year
- RIGL $15.97
- SPOK $2.54
- P/E Ratio
- RIGL $9.41
- SPOK $22.64
- Revenue Growth
- RIGL 70.16
- SPOK N/A
- 52 Week Low
- RIGL $8.10
- SPOK $13.55
- 52 Week High
- RIGL $29.82
- SPOK $18.29
- Technical
- Relative Strength Index (RSI)
- RIGL 45.79
- SPOK 52.90
- Support Level
- RIGL $18.24
- SPOK $17.33
- Resistance Level
- RIGL $19.38
- SPOK $18.22
- Average True Range (ATR)
- RIGL 0.77
- SPOK 0.43
- MACD
- RIGL -0.04
- SPOK 0.01
- Stochastic Oscillator
- RIGL 43.64
- SPOK 49.16
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About SPOK Spok Holdings Inc.
Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.